Poll: How Much Do You Know About Muscarinic Receptor Agonists?

Key Takeaways

• KarXT is a novel muscarinic acetylcholine receptor agonist developed by Bristol Myers Squibb for schizophrenia treatment.
• The US FDA is reviewing the New Drug Application for KarXT, focusing on its efficacy and safety.
• Muscarinic receptor agonists represent a new therapeutic approach for managing schizophrenia symptoms.
• Understanding the mechanism and clinical implications of muscarinic receptor agonists is essential for healthcare professionals.